A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Sensei Biotherapeutics, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 15,366 shares of SNSE stock, worth $9,065. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,366
Previous 23,864 35.61%
Holding current value
$9,065
Previous $25,000 64.0%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$0.59 - $1.84 $5,013 - $15,636
-8,498 Reduced 35.61%
15,366 $9,000
Q1 2024

May 15, 2024

SELL
$0.73 - $1.17 $1,415 - $2,268
-1,939 Reduced 7.51%
23,864 $25,000
Q4 2023

Feb 14, 2024

BUY
$0.53 - $0.82 $13,675 - $21,158
25,803 New
25,803 $17,000

Others Institutions Holding SNSE

About Sensei Biotherapeutics, Inc.


  • Ticker SNSE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,720,300
  • Market Cap $18.1M
  • Description
  • Sensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune res...
More about SNSE
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.